In this article, we will discuss Durvalumab (Warnings-20). So, let’s get started.
Thyroiditis: Immune-mediated thyroiditis occurred in 0.5% (9/1889) of patients receiving Durvalumab, including Grade 3 (<0.1%) adverse reactions. Events resolved in 4 of the 9 patients and resulted in permanent discontinuation in 1 patient. Systemic corticosteroids were required in 3 patients (3/9) with immune-mediated thyroiditis, while 8 patients (8/9) required endocrine therapy.